JP2004508365A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004508365A5 JP2004508365A5 JP2002525133A JP2002525133A JP2004508365A5 JP 2004508365 A5 JP2004508365 A5 JP 2004508365A5 JP 2002525133 A JP2002525133 A JP 2002525133A JP 2002525133 A JP2002525133 A JP 2002525133A JP 2004508365 A5 JP2004508365 A5 JP 2004508365A5
- Authority
- JP
- Japan
- Prior art keywords
- sulfamoyl
- alkyl
- formula
- compound
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 nitro, cyano, hydroxy, amino, carboxy, carbamoyl Chemical group 0.000 claims 89
- 125000000217 alkyl group Chemical group 0.000 claims 38
- 150000001875 compounds Chemical class 0.000 claims 29
- 150000002148 esters Chemical class 0.000 claims 24
- 238000001727 in vivo Methods 0.000 claims 24
- 150000003839 salts Chemical class 0.000 claims 24
- 125000003545 alkoxy group Chemical group 0.000 claims 17
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 16
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 229910052757 nitrogen Inorganic materials 0.000 claims 15
- 125000005843 halogen group Chemical group 0.000 claims 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 4
- 125000005236 alkanoylamino group Chemical group 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 3
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 3
- 125000001589 carboacyl group Chemical group 0.000 claims 3
- 208000032839 leukemia Diseases 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 230000035755 proliferation Effects 0.000 claims 3
- 210000002307 prostate Anatomy 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 230000022131 cell cycle Effects 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 150000003230 pyrimidines Chemical class 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims 1
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 claims 1
- SGMLRJXBDRNXBJ-UHFFFAOYSA-N 4-[[4-(2,3-dimethylimidazol-4-yl)pyrimidin-2-yl]amino]-n-(2,2,2-trifluoroethyl)benzenesulfonamide Chemical compound CN1C(C)=NC=C1C1=CC=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC(F)(F)F)=N1 SGMLRJXBDRNXBJ-UHFFFAOYSA-N 0.000 claims 1
- KVJXNCXRESCVKS-UHFFFAOYSA-N 4-[[4-(3-ethyl-2-methylimidazol-4-yl)pyrimidin-2-yl]amino]-n-(2-methoxyethyl)benzenesulfonamide Chemical compound CCN1C(C)=NC=C1C1=CC=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCOC)=N1 KVJXNCXRESCVKS-UHFFFAOYSA-N 0.000 claims 1
- HIDAXOGGMZCOCG-UHFFFAOYSA-N 4-[[4-(3-ethyl-2-methylimidazol-4-yl)pyrimidin-2-yl]amino]-n-(3-methoxypropyl)benzenesulfonamide Chemical compound CCN1C(C)=NC=C1C1=CC=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCCOC)=N1 HIDAXOGGMZCOCG-UHFFFAOYSA-N 0.000 claims 1
- 206010051113 Arterial restenosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000022873 Ocular disease Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010061481 Renal injury Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims 1
- 230000000893 fibroproliferative effect Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000037806 kidney injury Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- BUPDQZDNTBNFFR-UHFFFAOYSA-N n-(cyclopropylmethyl)-4-[[4-(2,3-dimethylimidazol-4-yl)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound CN1C(C)=NC=C1C1=CC=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC2CC2)=N1 BUPDQZDNTBNFFR-UHFFFAOYSA-N 0.000 claims 1
- ZJDZXCYQBNODMM-UHFFFAOYSA-N n-(cyclopropylmethyl)-4-[[4-(3-ethyl-2-methylimidazol-4-yl)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound CCN1C(C)=NC=C1C1=CC=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC2CC2)=N1 ZJDZXCYQBNODMM-UHFFFAOYSA-N 0.000 claims 1
- QSHDCKRJZSDIGZ-UHFFFAOYSA-N n-(cyclopropylmethyl)-4-[[4-(3-methyl-2-propan-2-ylimidazol-4-yl)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound CN1C(C(C)C)=NC=C1C1=CC=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC2CC2)=N1 QSHDCKRJZSDIGZ-UHFFFAOYSA-N 0.000 claims 1
- DYOCFCUPENQNPU-UHFFFAOYSA-N n-cyclobutyl-4-[[4-(2,3-dimethylimidazol-4-yl)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound CN1C(C)=NC=C1C1=CC=NC(NC=2C=CC(=CC=2)S(=O)(=O)NC2CCC2)=N1 DYOCFCUPENQNPU-UHFFFAOYSA-N 0.000 claims 1
- PDPLSGKAGFEBII-UHFFFAOYSA-N n-cyclobutyl-4-[[4-(2-methyl-3-propan-2-ylimidazol-4-yl)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound CC(C)N1C(C)=NC=C1C1=CC=NC(NC=2C=CC(=CC=2)S(=O)(=O)NC2CCC2)=N1 PDPLSGKAGFEBII-UHFFFAOYSA-N 0.000 claims 1
- YUBLGYSOQYIMIG-UHFFFAOYSA-N n-cyclopropyl-4-[[4-(2,3-dimethylimidazol-4-yl)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound CN1C(C)=NC=C1C1=CC=NC(NC=2C=CC(=CC=2)S(=O)(=O)NC2CC2)=N1 YUBLGYSOQYIMIG-UHFFFAOYSA-N 0.000 claims 1
- MDUHIEIIDZPVRB-UHFFFAOYSA-N n-cyclopropyl-4-[[4-(3-ethyl-2-methylimidazol-4-yl)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound CCN1C(C)=NC=C1C1=CC=NC(NC=2C=CC(=CC=2)S(=O)(=O)NC2CC2)=N1 MDUHIEIIDZPVRB-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 210000003905 vulva Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0021726.5A GB0021726D0 (en) | 2000-09-05 | 2000-09-05 | Chemical compounds |
| GB0021726.5 | 2000-09-05 | ||
| PCT/GB2001/003864 WO2002020512A1 (en) | 2000-09-05 | 2001-08-30 | Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004508365A JP2004508365A (ja) | 2004-03-18 |
| JP3523641B2 JP3523641B2 (ja) | 2004-04-26 |
| JP2004508365A5 true JP2004508365A5 (enExample) | 2005-04-07 |
Family
ID=9898838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002525133A Expired - Fee Related JP3523641B2 (ja) | 2000-09-05 | 2001-08-30 | 抗細胞増殖薬としてのイミダゾロ−５−イル−２−アニリノ−ピリミジン類 |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US6969714B2 (enExample) |
| EP (1) | EP1351958B1 (enExample) |
| JP (1) | JP3523641B2 (enExample) |
| KR (1) | KR100802368B1 (enExample) |
| CN (1) | CN1269813C (enExample) |
| AR (1) | AR033836A1 (enExample) |
| AT (1) | ATE269327T1 (enExample) |
| AU (2) | AU2001284192B2 (enExample) |
| BG (1) | BG107579A (enExample) |
| BR (1) | BR0113496A (enExample) |
| CA (1) | CA2417148C (enExample) |
| CZ (1) | CZ2003617A3 (enExample) |
| DE (1) | DE60103935T2 (enExample) |
| DK (1) | DK1351958T3 (enExample) |
| EE (1) | EE05430B1 (enExample) |
| ES (1) | ES2221904T3 (enExample) |
| GB (1) | GB0021726D0 (enExample) |
| HU (1) | HUP0302922A3 (enExample) |
| IL (1) | IL154292A0 (enExample) |
| IS (1) | IS2055B (enExample) |
| MX (1) | MXPA03001511A (enExample) |
| MY (1) | MY127126A (enExample) |
| NO (1) | NO324059B1 (enExample) |
| NZ (1) | NZ523787A (enExample) |
| PL (1) | PL360627A1 (enExample) |
| PT (1) | PT1351958E (enExample) |
| RU (1) | RU2284327C2 (enExample) |
| SK (1) | SK287277B6 (enExample) |
| TW (1) | TWI242559B (enExample) |
| UA (1) | UA74206C2 (enExample) |
| WO (1) | WO2002020512A1 (enExample) |
| ZA (1) | ZA200300612B (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004886D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| US7122544B2 (en) * | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
| US7129242B2 (en) | 2000-12-06 | 2006-10-31 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
| JP2005524672A (ja) * | 2002-03-09 | 2005-08-18 | アストラゼネカ アクチボラグ | Ｃｄｋ阻害活性を有するイミダゾリル置換ピリミジン誘導体 |
| GB0205693D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205690D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205688D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| AR039241A1 (es) * | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| DE10239042A1 (de) * | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| UA80295C2 (en) * | 2002-09-06 | 2007-09-10 | Biogen Inc | Pyrazolopyridines and using the same |
| GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| GB0311274D0 (en) * | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| GB0311276D0 (en) * | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| GB0402277D0 (en) * | 2004-02-03 | 2004-03-10 | Astrazeneca Ab | Chemical compounds |
| TW200528101A (en) * | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
| KR20070084067A (ko) * | 2004-10-13 | 2007-08-24 | 와이어쓰 | Ｎ-벤젠설포닐 치환 아닐리노-피리미딘 동족체 |
| EP1804803A4 (en) * | 2004-10-28 | 2008-07-30 | Irm Llc | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG WALK MODULATORS |
| US20090099160A1 (en) * | 2004-12-17 | 2009-04-16 | David Andrews | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors |
| CN1939910A (zh) * | 2004-12-31 | 2007-04-04 | 孙飘扬 | 氨基嘧啶类化合物及其盐和其制备方法与药物用途 |
| GB0504753D0 (en) * | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| CA2617170A1 (en) | 2005-07-30 | 2007-02-08 | Astrazeneca Ab | Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders |
| KR100674813B1 (ko) * | 2005-08-05 | 2007-01-29 | 일양약품주식회사 | Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법 |
| BRPI0616722A2 (pt) | 2005-09-30 | 2012-12-25 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, processo para preparar o mesmo, composiÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel ou um Éster hidrolisÁvel in vivo do mesmo, e, mÉtodos para produzir um efeito anti-proliferaÇço celular e um efeito inibidor cdk2, para tratar cÂncer, e para tratar doenÇas |
| AR058073A1 (es) * | 2005-10-03 | 2008-01-23 | Astrazeneca Ab | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos |
| US20080214560A1 (en) * | 2005-10-03 | 2008-09-04 | Astrazeneca Ab | Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease |
| US20090111860A1 (en) * | 2006-04-21 | 2009-04-30 | Astrazeneca Ab | Sulfonamide compounds useful as adg receptor modulators |
| TW200811169A (en) * | 2006-05-26 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
| ATE482948T1 (de) | 2006-06-21 | 2010-10-15 | Astrazeneca Ab | Chemische verbindungen |
| TW200815418A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds I |
| TW200815417A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds II |
| BRPI0909041A2 (pt) * | 2008-03-14 | 2015-07-28 | Basf Se | Compostos, uso de compostos, processo para preparar compostos, composições agroquímicas, método para combater fungos fitopatogênicos, e, semente. |
| WO2010009139A2 (en) * | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Imidazolyl pyrimidine inhibitor compounds |
| CN101503402B (zh) * | 2009-03-10 | 2014-06-25 | 沈阳药科大学 | 2-苯胺嘧啶衍生物及其制备和用途 |
| US8178529B2 (en) | 2009-04-15 | 2012-05-15 | Astrazeneca Ab | Imidazole substituted pyrimidines |
| HUE029196T2 (en) | 2010-06-04 | 2017-02-28 | Hoffmann La Roche | Aminoprimidine derivatives as LRRK2 modulators |
| SG189043A1 (en) | 2010-11-10 | 2013-05-31 | Hoffmann La Roche | Pyrazole aminopyrimidine derivatives as lrrk2 modulators |
| CN106928192B (zh) * | 2015-12-29 | 2020-11-13 | 中国科学院广州生物医药与健康研究院 | 一种嘧啶类化合物及其制备方法和应用 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| US11472791B2 (en) | 2019-03-05 | 2022-10-18 | Incyte Corporation | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| MX2022001940A (es) | 2019-08-14 | 2022-05-10 | Incyte Corp | Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2. |
| CN119930610A (zh) | 2019-10-11 | 2025-05-06 | 因赛特公司 | 作为cdk2抑制剂的双环胺 |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| CN116528869A (zh) * | 2020-11-27 | 2023-08-01 | 安锐生物医药科技(广州)有限公司 | 氨基杂芳基激酶抑制剂 |
| JP2024523892A (ja) * | 2021-06-16 | 2024-07-02 | ブループリント メディシンズ コーポレイション | Ｃｄｋ２阻害剤としての置換ピリミジニルーピラゾール |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| CN113999210B (zh) * | 2021-12-03 | 2023-05-23 | 郑州大学第一附属医院 | 一组2-苯氨基-4-三氮唑基嘧啶类衍生物及其应用 |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
| CN116751167B (zh) * | 2023-07-03 | 2025-09-23 | 苏州诚和医药化学有限公司 | 一种(e)-4-(1-苄基-2-甲基-1h-咪唑-5-基)-3-(乙氧基酰基)丁-3-烯酸的制备方法 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4659363A (en) | 1983-07-25 | 1987-04-21 | Ciba-Geigy Corporation | N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof |
| US4946956A (en) | 1988-09-21 | 1990-08-07 | Uniroyal Chemical Company, Inc. | Arylenediamine substituted pyrimidines |
| HU206337B (en) | 1988-12-29 | 1992-10-28 | Mitsui Petrochemical Ind | Process for producing pyrimidine derivatives and pharmaceutical compositions |
| US4983608A (en) | 1989-09-05 | 1991-01-08 | Hoechst-Roussell Pharmaceuticals, Inc. | N-substituted-4-pyrimidinamines and pyrimidinediamines |
| GB9012592D0 (en) | 1990-06-06 | 1990-07-25 | Smithkline Beecham Intercredit | Compounds |
| AU658646B2 (en) | 1991-05-10 | 1995-04-27 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| US5516775A (en) | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
| PT664291E (pt) | 1992-10-05 | 2000-11-30 | Ube Industries | Composto de pirimidina |
| IL110296A (en) * | 1993-07-16 | 1999-12-31 | Smithkline Beecham Corp | Imidazole compounds process for their preparation and pharmaceutical compositions containing them |
| US5543520A (en) | 1993-10-01 | 1996-08-06 | Ciba-Geigy Corporation | Pyrimidine derivatives |
| DE69434721T2 (de) | 1993-10-01 | 2006-11-09 | Novartis Ag | Pharmacologisch wirksame pyrimidinderivate und verfahren zu deren herstellung |
| DK0672041T3 (da) | 1993-10-01 | 2002-02-25 | Novartis Ag | Farmakologisk aktive pyridinderivater og fremgangsmåder til fremstilling deraf |
| EP0672035A1 (en) | 1993-10-01 | 1995-09-20 | Novartis AG | Pyrimidineamine derivatives and processes for the preparation thereof |
| GB9325217D0 (en) | 1993-12-09 | 1994-02-09 | Zeneca Ltd | Pyrimidine derivatives |
| US5494998A (en) | 1994-11-14 | 1996-02-27 | Akzo Nobel N.V. | Polymerization of carbon monoxide and ethylene using catalyst containing non-coordinating, non-acidic anion |
| ATE251141T1 (de) | 1995-03-10 | 2003-10-15 | Berlex Lab | Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien |
| US5739143A (en) | 1995-06-07 | 1998-04-14 | Smithkline Beecham Corporation | Imidazole compounds and compositions |
| US5658903A (en) | 1995-06-07 | 1997-08-19 | Smithkline Beecham Corporation | Imidazole compounds, compositions and use |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| JP2000507558A (ja) | 1996-03-25 | 2000-06-20 | スミスクライン・ビーチャム・コーポレイション | Ｃｎｓ損傷についての新規な治療 |
| AU2381397A (en) | 1996-04-19 | 1997-11-12 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
| TW440563B (en) | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
| EP0906307B1 (en) * | 1996-06-10 | 2005-04-27 | Merck & Co., Inc. | Substituted imidazoles having cytokine inhibitory activity |
| GB9619284D0 (en) | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
| AU5147598A (en) | 1996-10-17 | 1998-05-11 | Smithkline Beecham Corporation | Methods for reversibly inhibiting myelopoiesis in mammalian tissue |
| GB9622363D0 (en) | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
| ZA9711092B (en) | 1996-12-11 | 1999-07-22 | Smithkline Beecham Corp | Novel compounds. |
| DE69839338T2 (de) | 1997-02-05 | 2008-07-10 | Warner-Lambert Company Llc | Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation |
| DE19710435A1 (de) | 1997-03-13 | 1998-09-17 | Hoechst Ag | Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen |
| GB9705361D0 (en) | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
| AU734009B2 (en) | 1997-05-30 | 2001-05-31 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| PT988301E (pt) | 1997-06-12 | 2006-10-31 | Aventis Pharma Ltd | Acetais ciclicos de imidazolilo |
| TW517055B (en) | 1997-07-02 | 2003-01-11 | Smithkline Beecham Corp | Novel substituted imidazole compounds |
| JP2001519345A (ja) | 1997-10-02 | 2001-10-23 | メルク エンド カムパニー インコーポレーテッド | プレニルタンパク質トランスフェラーゼの阻害剤 |
| EP1021173A1 (en) | 1997-10-10 | 2000-07-26 | Imperial College Innovations Limited | Use of csaid?tm compounds for the management of uterine contractions |
| DE69839735D1 (de) | 1997-12-15 | 2008-08-28 | Astellas Pharma Inc | Pyrimidin-5-carboxamid-derivate |
| AU1924699A (en) * | 1997-12-19 | 1999-07-12 | Smithkline Beecham Corporation | Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses |
| BR9908004A (pt) | 1998-02-17 | 2001-12-18 | Tularik Inc | Composto, composição e método para prevençãoou supressão de uma infecção viral |
| NZ506679A (en) | 1998-03-27 | 2002-11-26 | Janssen Pharmaceutica Nv | HIV inhibiting pyrimidine derivatives |
| GB9806739D0 (en) | 1998-03-28 | 1998-05-27 | Univ Newcastle Ventures Ltd | Cyclin dependent kinase inhibitors |
| DE69933680T2 (de) | 1998-08-29 | 2007-08-23 | Astrazeneca Ab | Pyrimidine verbindungen |
| DE69932828T2 (de) | 1998-08-29 | 2007-10-18 | Astrazeneca Ab | Pyrimidine verbindungen |
| JP2002527359A (ja) | 1998-09-18 | 2002-08-27 | ビーエーエスエフ アクチェンゲゼルシャフト | キナーゼインヒビターとしての４−アミノピロリピリミジン |
| AU6476599A (en) * | 1998-11-03 | 2000-05-22 | Novartis Ag | Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB9903762D0 (en) | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| US6627633B2 (en) | 1999-03-17 | 2003-09-30 | Albany Molecular Research, Inc. | 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents |
| GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
| GB9914258D0 (en) | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| GB9924862D0 (en) | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
| ES2254238T3 (es) | 1999-10-27 | 2006-06-16 | Novartis Ag | Compuestos de tiazol e imidazo(4,5-b)piridina y su uso farmaceutico. |
| HK1050190A1 (zh) | 1999-11-22 | 2003-06-13 | Smithkline Beecham Plc | 咪唑衍生物和它们做为raf激酶抑制剂的用途 |
| EP1246823A1 (en) | 1999-12-28 | 2002-10-09 | Pharmacopeia, Inc. | Pyrimidine and triazine kinase inhibitors |
| MXPA02007957A (es) | 2000-02-17 | 2002-11-29 | Amgen Inc | Inhibidores de cinasas. |
| GB0004888D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004886D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0007371D0 (en) | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| GB0103926D0 (en) | 2001-02-17 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| GB0113041D0 (en) | 2001-05-30 | 2001-07-18 | Astrazeneca Ab | Chemical compounds |
| WO2003040131A1 (en) * | 2001-11-07 | 2003-05-15 | F. Hoffmann-La Roche Ag | Aminopyrimidines and pyridines |
-
2000
- 2000-09-05 GB GBGB0021726.5A patent/GB0021726D0/en not_active Ceased
-
2001
- 2001-08-30 CN CNB018151744A patent/CN1269813C/zh not_active Expired - Fee Related
- 2001-08-30 NZ NZ523787A patent/NZ523787A/en unknown
- 2001-08-30 EP EP01963159A patent/EP1351958B1/en not_active Expired - Lifetime
- 2001-08-30 CA CA2417148A patent/CA2417148C/en not_active Expired - Fee Related
- 2001-08-30 BR BR0113496-5A patent/BR0113496A/pt not_active Application Discontinuation
- 2001-08-30 WO PCT/GB2001/003864 patent/WO2002020512A1/en not_active Ceased
- 2001-08-30 UA UA2003042977A patent/UA74206C2/uk unknown
- 2001-08-30 AT AT01963159T patent/ATE269327T1/de active
- 2001-08-30 HU HU0302922A patent/HUP0302922A3/hu unknown
- 2001-08-30 CZ CZ2003617A patent/CZ2003617A3/cs unknown
- 2001-08-30 US US10/363,655 patent/US6969714B2/en not_active Expired - Fee Related
- 2001-08-30 ES ES01963159T patent/ES2221904T3/es not_active Expired - Lifetime
- 2001-08-30 DE DE60103935T patent/DE60103935T2/de not_active Expired - Lifetime
- 2001-08-30 PL PL36062701A patent/PL360627A1/xx not_active Application Discontinuation
- 2001-08-30 DK DK01963159T patent/DK1351958T3/da active
- 2001-08-30 SK SK241-2003A patent/SK287277B6/sk not_active IP Right Cessation
- 2001-08-30 RU RU2003109612/04A patent/RU2284327C2/ru not_active IP Right Cessation
- 2001-08-30 KR KR1020037003215A patent/KR100802368B1/ko not_active Expired - Fee Related
- 2001-08-30 AU AU2001284192A patent/AU2001284192B2/en not_active Ceased
- 2001-08-30 IL IL15429201A patent/IL154292A0/xx not_active IP Right Cessation
- 2001-08-30 JP JP2002525133A patent/JP3523641B2/ja not_active Expired - Fee Related
- 2001-08-30 MX MXPA03001511A patent/MXPA03001511A/es active IP Right Grant
- 2001-08-30 EE EEP200300088A patent/EE05430B1/xx not_active IP Right Cessation
- 2001-08-30 AU AU8419201A patent/AU8419201A/xx active Pending
- 2001-08-30 PT PT01963159T patent/PT1351958E/pt unknown
- 2001-09-03 MY MYPI20014136 patent/MY127126A/en unknown
- 2001-09-05 AR ARP010104228A patent/AR033836A1/es unknown
- 2001-09-11 TW TW090122494A patent/TWI242559B/zh not_active IP Right Cessation
-
2003
- 2003-01-22 ZA ZA200300612A patent/ZA200300612B/en unknown
- 2003-02-12 IS IS6715A patent/IS2055B/is unknown
- 2003-02-21 BG BG107579A patent/BG107579A/bg unknown
- 2003-03-04 NO NO20031006A patent/NO324059B1/no not_active IP Right Cessation
-
2005
- 2005-06-29 US US11/169,197 patent/US20060004033A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004508365A5 (enExample) | ||
| RU2003109612A (ru) | Имидазоло-5-ил-2-анилино-примидины как агенты для ингибирования пролиферации клеток | |
| CA2417148A1 (en) | Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation | |
| JP2006518728A5 (enExample) | ||
| JP2003528861A5 (enExample) | ||
| RU2003103848A (ru) | Пиримидиновые производные | |
| RU2004130440A (ru) | Производные 4-(имидазол-5-ил)-2-(4-сульфоанилино)пиримидина, обладающие ингибирующим действием по отношению к cdk | |
| JP2008505874A5 (enExample) | ||
| JP2022043059A5 (enExample) | ||
| RU2004134564A (ru) | Химические соединения | |
| JP2015503529A5 (enExample) | ||
| JP2005538955A5 (enExample) | ||
| JP2004520324A5 (enExample) | ||
| JP2003525279A5 (enExample) | ||
| RU2004136977A (ru) | Производные пиридазин-3(2h)-она в качестве ингибиторов фосфодиэстеразы 4 (pde4) | |
| JP2006528962A5 (enExample) | ||
| RU2003127116A (ru) | Гетероциклические ингибиторы erk2 и их использование | |
| CA2483164A1 (en) | Pyrrolo-triazine aniline compounds useful as kinase inhibitors | |
| RU98100054A (ru) | Производные n-гетероарил-пиридинсульфонамида и их применение в качестве антагонистов эндотелина | |
| JP2009513703A5 (enExample) | ||
| RU2010110640A (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
| RU2004135064A (ru) | Новые замещенные индолы | |
| RU2006147267A (ru) | Конденсированное гетероциклическое соединение | |
| SI2824100T1 (en) | 1,2,5-oxadiazoles as inhibitors of indolamine 2,3-dioxygenase | |
| HRP20140309T1 (hr) | SUPSTITUIRANI SPOJEVI PIRAZOLO[1,5-a]PIRIMIDINA KAO INHIBITORI TRK KINAZE |